Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL-21Generic

GENCEPT 10/11-21

ETHINYL ESTRADIOL; NORETHINDRONE

Standard Dose
0.035MG,0.035MG;0.5MG,1MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview GENCEPT 10/11-21 is listed in Drugs@FDA under application 072694 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE Form and strength TABLET;ORAL-21 - 0.035MG,0.035MG;0.5MG,1MG Sponsor BARR Submission history Latest submission status date: 2022-04-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview GENCEPT 10/11-21 is listed in Drugs@FDA under application 072694 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE Form and strength TABLET;ORAL-21 - 0.035MG,0.035MG;0.5MG,1MG Sponsor BARR Submission history Latest submission status date: 2022-04-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
GENCEPT 10/11-21 (ETHINYL ESTRADIOL; NORETHINDRONE) | Drug Monograph | MedicHelpline